After years of the big pharma industry pushing diversification as the
solution to its woes, at least one major player is breaking from the
pack. Bristol-Myers Squibb (NYSE: BMY )
is prioritizing its oncology and virology assets, and the company has
already staked out some attractive real estate in the immuno-oncology
space. While the appeal and potential of immuno-oncology is legitimate,
the valuation is already generous and the company's lead on Merck and Roche may not be as strong as the bulls hope.
Please continue here:
The Bristol-Myers Squibb Co. Overreaction Highlights The Dependence On Oncology
No comments:
Post a Comment